Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Accepted for publication March 3, 2024
- Published online June 1, 2024.
Article Versions
- Latest version (March 15, 2024 - 04:00).
- Latest version (April 1, 2024 - 04:00).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2024 by the Journal of Rheumatology This is an Open Access article, which permits use, distribution, and reproduction, without modification, provided the original article is correctly cited and is not used for commercial purposes.
Author Information
- 1L.K. Stamp, PhD, Department of Medicine, University of Otago, Christchurch;
- 2N. Dalbeth, MD, Faculty of Medicine, University of Auckland, Auckland, New Zealand.
- Address correspondence to Prof. L.K. Stamp, Department of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8014, New Zealand. Email: lisa.stamp{at}cdhb.health.nz.
Article usage
Statistics from Altmetric.com
In this issue
Jump to section
- Article
- Abstract
- Currently available ULTs and rank order for use
- What do allopurinol success and failure look like?
- Failure of allopurinol to achieve target SU
- Failure to achieve the desired clinical outcomes despite reducing the SU to target
- Adverse reaction requiring cessation of allopurinol
- What is the approach to allopurinol failure?
- Conclusion
- Footnotes
- REFERENCES
- Figures & Data
- Info & Metrics
- References